Tag: Hepatitis C treatment

Understanding prescribing trends for hepatitis C treatment in Ontario

The introduction and wide availability of direct-acting antivirals (DAAs) as a treatment for hepatitis C through a phased rollout from 2015 to 2018 held the promise of expanded access to treatment. These simpler treatments carried fewer clinical restrictions and required less specialist support, opening the possibility for primary care providers to treat their patients with hepatitis C. Given barriers to healthcare access for people who use drugs, those of us at the Toronto Community Hep C Program were curious to find out if this had in fact happened.

Read more

Five ways to sustain the hepatitis C elimination efforts in Canada

This June, CATIE and the Canadian Network on Hepatitis C (CanHepC) co-hosted a webinar on sustaining the hepatitis C response before and after the novel coronavirus disease (COVID-19) pandemic. We invited leaders in the hepatitis C field to explore the challenges that the pandemic has posed for hepatitis C elimination efforts, but also the opportunities that could be leveraged. Here are just five of the ways we can do this:

Read more

Five ideas to scale up hepatitis C services in Canada

Hepatitis C is curable. Today’s treatment regimens are highly effective and easy to complete. And it has the added benefit of preventing transmission to others, making it possible to eliminate hepatitis C from Canada. However, for many of the most marginalized people affected by hepatitis C in Canada, including people who use drugs, treatment remains frustratingly out of reach. Those who are most at risk are also the ones most often missed by healthcare services.

Read more

INHSU 2019: Wholistic hepatitis C care, and the importance of care providers

Hundreds of clinicians, researchers and people with lived experience gathered in Montreal in September 2019 to highlight promising work in hepatitis C research and practice. The 8th International Conference on Hepatitis Care in Substance Users (INHSU 2019) showcased innovative models of care that support the delivery of hepatitis C treatment.

Read more

Meeting people where they are is about much more than location: Delivering hepatitis C care and treatment to people who use drugs

Poverty, stigma and criminalization are chronic problems among people who use and inject drugs. But hepatitis C virus (HCV) is no longer such a problem, since it is usually cured by eight to 12 weeks of oral, direct-acting antivirals (DAAs). Delivering DAAs to people who use and inject drugs in the context of the chronic problems facing them is an opportunity to recognize and support the contribution of people with lived experience, and to build and strengthen systems and programs.

Read more